FDA has reported adverse events, including hospitalizations, linked to dosing errors with compounded injectable semaglutide.
What FDA reported
FDA received reports of adverse events, some requiring hospitalization, that may be related to overdoses caused by dosing errors with compounded injectable semaglutide.
Why dosing can be confusing
Compounded products may come in vials with concentrations and measuring devices that differ from prefilled brand-name pens. Confusion between units, milliliters and milligrams can create risk.
Safer process
- Use only the prescribed concentration
- Have the clinician or pharmacist demonstrate measurement
- Use the supplied/appropriate syringe
- Do not convert units on your own
- Contact the care team if the instructions are unclear
Sources & verification
We use primary sources for time-sensitive commercial and regulatory claims.
- FDA — Dosing errors associated with compounded injectable semaglutide
- FDA — Concerns with unapproved GLP-1 drugs used for weight loss
Last reviewed: August 19, 2026